Ramara Walker

Ramara Walker

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
RWRamara Walker
Ramara Walker
SBStephanie Bass
Stephanie Bass
PSPavithra Srinivas
Pavithra Srinivas
CMCyndee Miranda
Cyndee Miranda
LJLucileia Johnson
Lucileia Johnson
APAndrea M. Pallotta
Andrea M. Pallotta
Background: Centers for Disease Control and Prevention recommends 3 months of once-weekly rifapentine/isoniazid (3HP) for latent tuberculosis infection (LTBI) treatment given by directly observed therapy (DOT) or self-administered therapy (SAT) in patients ≥2 years old. 3HP has been associated with increased incidence of hepatic, gastrointestinal, flu-like, and cutaneous adverse drug reactions (ADRs) compared with isoniazid monotherapy. Objective: This study evaluated 3HP completion rates and tolerability for LTBI treatment in a real-world setting. Methods: A single-center retrospective cohort with a nested case-control study, comparing patients experiencing ADRs with those who did not, evaluated patients ≥18 years old receiving 3HP by DOT or SAT for LTBI at Cleveland Clinic from October 2011 through July 2018. Information on baseline characteristics, 3HP administrations, and ADRs were collected. Results: Of 199 patients screened, 144 were included (111 DOT, 33 SAT). 3HP completion rates were high at 82.6% and similar between DOT and SAT groups. During treatment, 92/144 (63.9%) patients experienced any ADR. The most common ADR included flu-like symptoms (38.2%) and gastrointestinal (31.9%) and hepatic (2.1%) reactions. Despite high rate of overall ADRs, rates of significant ADRs (grade 2 or higher) were 4.2%. Overall, 9% of patients discontinued 3HP because of ADRs. After adjusting for other factors associated with ADRs at baseline, SAT was not associated with increased incidence of ADRs, but female sex was a significant predictor (odds ratio = 2.61 [95% CI, 1.23 to 5.56]). Conclusion and Relevance: This study observed high 3HP treatment completion rates, low incidence of significant ADRs, and low discontinuation rates resulting from ADRs.

15 April 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
ADAbhishek Deshpande
Abhishek Deshpande
RSRebecca Schulte
Rebecca Schulte
RWRamara Walker
Ramara Walker
APAndrea M Pallotta
Andrea M Pallotta
MWMing Wang
Ming Wang
MRMichael B Rothberg
Michael B Rothberg
Background: Procalcitonin (PCT) testing may guide antibiotic decisions in community-acquired pneumonia (CAP), but real-world evidence of its impact on antibiotic prescribing in the era of shorter antibiotic courses remains limited. Methods: We conducted a retrospective cohort study of adults with CAP admitted to the wards of 12 hospitals between November 2022 and January 2025. Primary analyses included: (1) PCT testing rates at admission, (2) the association between PCT testing and duration of antibiotic therapy, and (3) among patients initiated on extended-spectrum antibiotics (ESAs), the relationship between PCT results and early de-escalation. We compared outcomes between PCT-tested and untested patients and between those with low (<0.1 μg/L) vs high (≥0.1 μg/L) PCT values using propensity score overlap weighting to control for potential confounders. Results: Among 17 290 non–intensive care unit (ICU) admissions for CAP, PCT testing was performed for 10 658 patients (59.5%) within 24 hours of admission. After adjustments, PCT testing was associated with shorter antibiotic duration (adjusted mean difference, −0.32 days; 95% confidence interval [CI], −.52 to −.12) but was not significantly associated with ESA de-escalation compared with no PCT testing (hazard ratio, 1.05; 95% CI, .99–1.12). Patients with low PCT values received shorter antibiotic courses compared with those with high values (adjusted mean difference, −0.56 days; 95% CI, −.85 to −.49). Conclusions: In non-ICU patients with CAP, PCT testing was associated with modest differences in antibiotic duration, primarily when values were low.

17 October 2024 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
RWRamara Walker
Ramara Walker
RSRebecca Schulte
Rebecca Schulte
APAndrea M. Pallotta
Andrea M. Pallotta
LTLarisa G. Tereshchenko
Larisa G. Tereshchenko
VCVictoria A. Criswell
Victoria A. Criswell
MRMichael B. Rothberg
Michael B. Rothberg
Background: Community-acquired pneumonia (CAP) is a leading cause of hospitalizations and mortality in the US. Overuse of extended spectrum antibiotics (ESA) for CAP contributes to antimicrobial resistance. The 2019 Infectious Diseases Society of America/American Thoracic Society CAP guidelines emphasize de-escalation of ESA following negative cultures, early switch to oral (PO) antibiotics, and limited duration of therapy (DOT). This study describes clinicians’ acceptance of an infectious diseases-trained (ID) pharmacist-led stewardship recommendations in hospitalized patients with CAP. Methods: This prospective, single-arm, cohort study included adults admitted with a diagnosis of pneumonia to six Cleveland Clinic hospitals receiving ID pharmacist-led stewardship recommendations. The ID pharmacist provided recommendations for ESA de-escalation, DOT, intravenous (IV) to PO transition, and antimicrobial discontinuation. Descriptive statistics were used to describe clinician acceptance rates. Results: From November 1, 2022, to January 31, 2024, the ID pharmacist made recommendations for 685 patient encounters to 327 clinicians. Of these patients, 52% received an ESA and 15% had severe CAP. There were 959 recommendations: ESA de-escalation (19%), DOT (46%), IV to PO transition (19%), antimicrobial discontinuation (13%), and other (3%). Clinicians accepted 693 recommendations (72%): IV to PO transition (148/184, 80%), ESA de-escalation (141/181 78%), antimicrobial discontinuation (94/128, 73%), DOT (286/437, 65%), and other (24/29, 83%). Conclusion: Clinicians were generally receptive to ID pharmacist-led CAP recommendations with an overall acceptance rate of 72%. Prescribers were most receptive to recommendations for IV to PO conversion and least receptive to limiting DOT.

19 October 2026 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
JSJad Saab
Jad Saab
RSRebecca Schulte
Rebecca Schulte
MPMatthew A. Pappas
Matthew A. Pappas
MWMing Wang
Ming Wang
RWRamara Walker
Ramara Walker
MRMichael B. Rothberg
Michael B. Rothberg
Background: Real-world evidence is limited regarding the use and impact of procalcitonin (PCT) on antibiotic duration in severe community-acquired pneumonia (SCAP) patients. Methods: A retrospective cohort study of adult patients with SCAP (defined by modified American Thoracic Society [ATS] criteria) to 12 hospitals between November 2022 and June 2025. We analyzed clinical characteristics and estimated the association between PCT testing within 24 hours of hospital admission and antibiotic duration, and between low (<.5 µg/L) and high (≥.5 µg/L) PCT values and antibiotic duration. Clinical stability was determined based on ATS criteria (temperature <100 °F with ≤1 sign of instability within 24 hours of admission). Results: Among 1,553 SCAP admissions, 325 (21%) were clinically stable on admission and 924 patients (59.5%) had PCT testing within 24 hours; 452 (48.9%) of PCTs were low. Clinical stability was not associated with testing. PCT testing was associated with fewer antibiotic days (mean 6.9 vs 7.4 days adjusted mean difference, −.5 days, 95% CI: −.8, −.3), particularly in stable (mean 6.6 vs 7.3 days, adjusted mean difference, −.8 days, 95% CI: −1, −.1) versus unstable patients (mean 7.2 vs 7.5 days, adjusted mean difference, −.4 days, 95% CI: −.8, −.05). Low PCT values were associated with shorter antibiotic durations than high values (mean 6.5 vs 7.6 days, adjusted mean difference, −1.1 days, 95% CI: −1.9, −.3). Conclusions: PCT testing was associated with shorter antibiotic duration, especially among stable patients, but was performed without regard to clinical stability. Reserving PCT testing for stable patients may improve efficiency.

9 December 2025 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
RWRamara Walker
Ramara Walker
RSRebecca Schulte
Rebecca Schulte
APAndrea M. Pallotta
Andrea M. Pallotta
MWMing Wang
Ming Wang
ADAbhishek Deshpande
Abhishek Deshpande
MRMichael Rothberg
Michael Rothberg
Objective: Community-acquired pneumonia (CAP) is a leading cause of hospitalization and mortality in the US. Studies report racial disparities in various infectious syndromes. Our objective was to assess the relationship between patient race and antibiotic prescribing in inpatient CAP management. Design: Retrospective cohort study. Setting: 11 Cleveland Clinic community hospitals. Patients: Patients aged ≥18 years hospitalized with CAP between November 1, 2022, and January 31, 2025. Methods: Parametric and non-parametric methods were used to describe demographic and clinical differences by race. The association between race and extended spectrum antibiotic (ESA) guideline concordance was assessed using multivariable logistic regression models adjusting for age, gender, admission source, area deprivation index (ADI), hospital, diabetes, cardiovascular disease, chronic respiratory disease, renal failure, liver disease, immunocompromising condition, alcohol and substance use disorder, dialysis, and clinical instability and severity on day 1. Results: In bivariate analyses, Non-Hispanic Black (NHB) patients were less likely than NHW patients to receive ESA guideline-concordant CAP therapy (63.2% vs 64.4%; OR = 0.91, P = .2). After adjusting for patient characteristics, there were no differences between NHB and NHW patients in receipt of ESA therapy (adjusted OR = 0.93; 95% CI = 0.83, 1.00). After adjusting for hospital, NHB patients were more likely to receive ESA guideline-concordant CAP therapy (adjusted OR = 1.17; 95% CI = 1.06, 1.30). Conclusion: NHB patients were more likely to receive ESA-guideline concordant therapy, but this was influenced by where they sought care. Further studies are needed to understand why prescribing varies across hospitals.

2 July 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
ADAbhishek Deshpande
Abhishek Deshpande
RSRebecca Schulte
Rebecca Schulte
RWRamara Walker
Ramara Walker
APAndrea M Pallotta
Andrea M Pallotta
MKMichael Klompas
Michael Klompas
MRMichael B Rothberg
Michael B Rothberg